Compare Packaging Corporation of America (PKG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Packaging Corporation of America vs Vertex Pharmaceuticals Incorporated — how do they compare? Packaging Corporation of America trades at $227.95 (market cap $20.67B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.5× Packaging Corporation of America's market cap, and Packaging Corporation of America pays a 2.59% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| PKG | VRTX | |
|---|---|---|
Market Cap | $20.67B | $134.06B |
Sector | Technology | Health |
52-Week High | $257.43 | $557.96 |
52-Week Low | $191.68 | $376.62 |
Enterprise Value | $24.48B | $128.18B |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Packaging Corporation of America (PKG) trades at $231.99, down 2.22% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 30.13 above industry averages, while profitability metrics indicate solid ROE of 14.79% amid margin pressures. Recent news highlights dividend declarations and CEO participation in industry conferences, though cash flow trends show negative net flows driven by significant capital investments.
PKG presents a cautious outlook with analyst consensus leaning hold (57.69%) despite a $272.83 price target suggesting 17.6% upside. Investment appeal hinges on execution amid cost headwinds, while risks include margin compression and competitive pressures. The technical setup near support at $230 requires monitoring for potential breakdown or reversal signals.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
